

Ergotism With Ischemia In All Four Extremities: A Case Report

Seok-Young Jeong, M.D., Eui-Seong Lim, M.D., Byoung-Soo Shin, M.D.,
Man-Wook Seo, M.D., Young-Hyun Kim, M.D., Hyo-Sung Kwak, M.D.*,
Gyung-Ho Chung*, M.D., Seul-Ki Jeong, M.D.

Department of Neurology and Diagnostic Radiology, Chonbuk National University
Medical School, Jeonju, South Korea*

Here we describe a case of ergotism that presented with ischemia in all four extremities. A 48-year-old man was admitted for pain and weakness in both upper extremities. He had a long history of migraine and had taken 3 mg of ergotamine daily for more than 21 years. Angiography demonstrated vasospasm involving all four extremities, which resolved partially following intra-arterial prostaglandin infusion. Intravenous nitroprusside was administered, and the patient stopped smoking and stopped taking ergotamine in an attempt to counteract the vasospasm. Follow-up computed tomography angiogram revealed that both brachial arteries had normalized. Thus, in this case of ergotism, severe vasospasm in all of the extremities was resolved with appropriate management.

J Clin Neurol 2(4):279-282, 2006

Key Words : Ergotism, Vasospasm, Angiography

INTRODUCTION

Ergotamine has been used widely for the treatment of migraine, even though triptan derivatives have been accepted as the most effective agents for the relief of acute migraine attacks.¹ Ergotism is a sustained vasospasm induced by ergot medication, and is very rare, but has been observed in various situations, mainly as a result of ergotamine overuse,² idiosyncratic hypersensitivity reaction with therapeutic doses,³ and during concomitant use of other kinds of medication.⁴ The sustained arterial spasm observed in ergotism causes vascular insufficiency in the extremities, which is

characterized by pallor, coolness, numbness, and claudication if not treated promptly, the affected limb(s) may develop dry gangrene and, less commonly, suppurative gangrene and sepsis.⁵

To treat ergotism, it is mandatory to discontinue the ergotamine as well as other provocative factors, and then a therapeutic strategy should be established to control the withdrawal symptoms and migraine.¹ In cases of acute ergot toxicity, various levels of success have been reported with other treatment options, including calcium channel blockers, oral prazosin hydrochloride, alpha adrenergic blockers, systemic vasodilator therapy with nitroprusside, prostacyclin, and prostaglandin E.^{6,7}

Here we describe a patient with ergotism who pre-

Received : September 12, 2006 / Accepted : October 30, 2006 / Address for correspondence : Seul-Ki Jeong, M.D.

Department of Neurology, Research Institute of Clinical Medicine, Chonbuk National University Medical School and Hospital, San 2-20, Geumam-dong, Deokjin-gu, Jeonju, Chonbuk 561-712, South Korea

Tel: +82-63-250-1590, Fax: +82-63-251-9363, E-mail: jeongsk@chonbuk.ac.kr

* This study was supported by a grant from Chonbuk National University Hospital Research Institute of Clinical Medicine.

sented with typical angiographic findings involving both the upper and lower extremities, and who recovered after treatment, as assessed with the aid of improved vascular imaging.

CASE REPORT

A 48-year-old man was hospitalized for acute pain and weakness in both upper extremities, which had begun 3 days previously. He had no prior history of type 2 diabetes mellitus, hypertension, dyslipidemia, or trauma. He was a current smoker consuming one pack daily for 30 years. Both of his upper extremities were pale and cold, with an absent radial pulse and markedly delayed capillary refill.

The patient had a long history of migraine without typical aura and had been taking 3 mg of ergotamine daily for more than 21 years, this had been prescribed

at the local psychiatry clinic. During the week prior to his admission, he had increased his daily ergotamine intake as a result of severe headache related to psychological stress. Neurologic examination revealed abnormal sensory findings: paresthesia, numbness, and splitting (sharp) pain in both forearms and hands, which was aggravated by repeated shoulder or hand motion. Laboratory findings were unremarkable except for leukocytosis (18,400/ μ L).

Emergency angiography of the upper and lower extremities revealed diffuse spasmodic narrowing along the proximal portions of both brachial arteries (Fig. 1A and B). At the distal portions of the right brachial artery, severe vasospasm and collateral formations were observed, and the ulnar and radial arteries were poorly visualized (Fig. 1C). Angiography of the lower extremities also revealed multifocal stenoses along the deep and superficial femoral arteries (Fig. 1D). The vascularity in the left hand was improved following




Figure 1. Angiographic findings in the upper and lower extremities. The proximal portions of the right (A) and left (B) brachial artery, showing the smoothly tapered brachial artery and diffuse “thread-like” narrowing. The distal portions of the right brachial artery exhibit severe vasospasm and collateral formation (C). Multifocal segmental narrowings are evident in both deep femoral arteries (D).



Figure 2. Angiographic findings in the left hand. The left hand exhibited poor vascular perfusion (A), which was markedly improved after prostaglandin E1 infusion (B).

infusion of prostaglandin E1 during the angiography (Fig. 2A and B), but the condition of the right upper extremity remained poor.

On the basis of the angiographic findings and the medication history, the patient was diagnosed as suffering from ergotism. During admission, smoking and all types of ergotamine and caffeine-containing drugs were discontinued. Intravenous nitroprusside was infused at a rate of 4 $\mu\text{g/kg/min}$, with itopride (50 mg) and propranolol (20 mg) also given twice daily. One day after the initiation of therapy, both radial pulses were palpable, and 2 days later the pain in the upper

extremities had subsided, with minimal paresthesia. Nitroprusside was infused for 3 days, and then topiramate (50 mg) and flunarizine (10 mg) were started to treat withdrawal headache. Seven days after admission, the patient was discharged with clinical improvement. One month later, both brachial arteries appeared normal in a three-dimensional computed tomography angiogram (Fig. 3).

Three months later, the patient complained of irritability, insomnia, loss of appetite and libido, and psychomotor slowing that impaired his work. He was diagnosed with major depression by a psychiatrist, who prescribed paroxetine (25 mg daily). Over a period of 1 month, the dosage was increased to 32.5 mg/day and the depressive symptoms slowly improved.



Figure 3. Follow-up upper-extremity computed tomography angiogram (three-dimensionally rendered). One month after cessation of ergotamine and nitroprusside infusion, both brachial arteries appeared normal.

DISCUSSION

Ergotism, the most notable toxic effect of ergotamine, causes vasospasm that can affect virtually any vessel, including the splanchnic circulation.^{1,5} In the present patient, angiography revealed thread-like narrowing with extensive collateral formation in the upper extremities, and segmental narrowing in the lower extremities. To the best of our knowledge, this is the first case of angiographically proven involvement of all four extremities,

even though the pain and weakness were confined to the upper extremities.

The patient had been taking 3 mg of ergotamine daily for more than 21 years. Although most ergot toxicity is associated with excessive dosing, ergotism has been reported after extremely small doses or therapeutic doses administered over a long period of time.^{3,8} Furthermore, the patient might suffer from chronic migraine and therefore overuse his medication, as suggested by Silberstein.⁹ Recent mental stress and increased intake of ergotamine might have provoked the ergot intoxication in our patient. However, the acute vascular insufficiency resolved rapidly after vasodilator infusion without any definitive complication, and the headache was managed with recommended conventional prophylactic regimens.¹⁰

The patient described here suffered from psychiatric symptoms, and the diagnosis of depression was made after the treatment of acute ergotism. About 80% of chronic migraineurs are reported to have current psychiatry comorbidity.² It is necessary to diagnose the psychiatric symptoms and add an antidepressant for appropriate management in chronic migraineurs and ergotism.

We present here a patient with ergotism, which was resolved by the discontinuation of ergotamine and infusion of a vasodilator, and which was diagnosed initially and followed up subsequently with vascular imaging.

REFERENCES

1. Tfelt-Hansen P, Saxena PR, Dahlof C, Pascual J, Lainez M, Henry P, et al. Ergotamine in the acute treatment of migraine: a review and European consensus. *Brain* 2000; 123:9-18.
2. Frediani F, Cannata AP, Magnoni A, Peccarisi C, Bussone G. The patient with medication overuse: clinical management problems. *Neurol Sci* 2003;242:S108-111.
3. Wells KE, Steed DL, Zajko AB, Webster MW. Recognition and treatment of arterial insufficiency from cafergot. *J Vasc Surg* 1986;4:8-15.
4. Fukui S, Coggia M, Goeau-Brissonniere O. Acute upper extremity ischemia during concomitant use of ergotamine tartrate and ampicillin. *Ann Vasc Surg* 1997;11:420-424.
5. Merhoff GC, Porter JM. Ergot intoxication: historical review and description of unusual clinical manifestations. *Ann Surg* 1974;180:773-779.
6. McKiernan TL, Bock K, Leya F, Grassman E, Lewis B, Johnson SA, et al. Ergot induced peripheral vascular insufficiency, non-interventional treatment. *Cathet Cardiovasc Diagn* 1994;31:211-214.
7. Garcia GD, Goff JM Jr, Hadro NC, O'Donnell SD, Greatorex PS. Chronic ergot toxicity: A rare cause of lower extremity ischemia. *J Vasc Surg* 2000;31:1245-1247.
8. Senter HJ, Lieberman AN, Pinto R. Cerebral manifestations of ergotism. Report of a case and review of the literature. *Stroke* 1976;7:88-92.
9. Silberstein SD. Chronic daily headache. *J Am Osteopath Assoc* 2005;105:23S-29S.
10. Evers S, Afra J, Frese A, Goadsby PJ, Linde M, May A, et al. EFNS guideline on the drug treatment of migraine - report of an EFNS task force. *Eur J Neurol* 2006;13: 560-572.